Investing.com -- TransCode Therapeutics (NASDAQ:RNAZ) stock surged 18% on Tuesday after the company published preclinical data showing its lead candidate TTX-MC138 demonstrated therapeutic potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback